How to get Delta under control?

18,255 Views | 178 Replies | Last: 4 yr ago by Zobel
cone
User Profile
Private Message
Ignore User Stop Ignoring
How long do you want to ignore this user?
24 hours One week Permanently Cancel
In reply to Teslag • 9:02a, 7/21/21
AG
and that illness evidence was symptoms not hospitalization
Reply Quote
Teslag
User Profile
Private Message
Ignore User Stop Ignoring
How long do you want to ignore this user?
24 hours One week Permanently Cancel
In reply to cone • 9:05a, 7/21/21
AG
I believe the efficacy studies had divided them into mild and severe symptoms with the efficacy based on severe.

For example, if you get a low fever from infection and that's it the vaccine was determined effective in the study.
Reply Quote
2
cone
User Profile
Private Message
Ignore User Stop Ignoring
How long do you want to ignore this user?
24 hours One week Permanently Cancel
In reply to Teslag • 9:45a, 7/21/21
AG
Quote:
For example, if you get a low fever from infection and that's it the vaccine was determined effective in the study.
Quote:
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study's primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.

There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
Reply Quote
Teslag
User Profile
Private Message
Ignore User Stop Ignoring
How long do you want to ignore this user?
24 hours One week Permanently Cancel
In reply to cone • 10:25a, 7/21/21
AG
Is there something in your link and quote that refutes what I said?
Reply Quote
Zobel
User Profile
Private Message
Ignore User Stop Ignoring
How long do you want to ignore this user?
24 hours One week Permanently Cancel
In reply to Teslag • 10:41a, 7/21/21
AG
The primary efficacy number in all the studies I've read has been symptomatic infection - one symptom like fever, cough, shortness of breath + positive PCR test.

They also frequently have a second number for efficacy at preventing severe covid (hospitalization or death).

So everyone is right.
Reply Quote
2
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.